Amino pyrazole compound

ABSTRACT

The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.

Janus kinase 2 (JAK2) is a member of the tyrosine kinase family which isinvolved in cytokine signaling. JAK2 has a pivotal role in theerythropoietin (EPO) signaling pathway, including erythrocytedifferentiation and Stat5 activation. Recent studies have demonstratedthat patients with chronic myeloproliferative disorders such aspolycythemia vera, essential thrombocytosis, and myelosclerosis withmyeloid metaplasia and thrombotic disorders such as activated protein Cresistance, splanchnic vein thrombosis, Budd-Chiari Syndrome, and portalvein thrombosis frequently have acquired activating mutations in JAK2.The mutation, a valine-to-phenylalanine substitution at amino acidposition 617, leads to constitutive tyrosine phosphorylation activity,by an unknown mechanism. The constitutive activity of mutant JAK2 leadsto increased levels of phosphorylated JAK2, pSTAT5, and STAT5transcriptional activity, which leads to the pathogenesis ofmyeloproliferative disorders and leukemias, such as atypical chronicmyeloid leukemia. In addition, JAK2 is activated byinterleukin-6-depedent autocrine loop or other genetic alterations insolid and hematologic tumors, e.g., glioblastoma, breast cancer,multiple myeloma, prostate cancer, primary and secondary acute myeloidleukemia, T-lineage and B-lineage acute lymphoblastic leukemia,myelodysplasia syndrome.

Various amino pyrazole tyrosine kinase inhibitors have been reported.See for example, WO06087538 and WO2007064797.

However, there is still a need for further compounds that inhibittyrosine kinases such as JAK2. The present invention provides a novelamino pyrazole compound believed to have clinical use for treatment ofmyeloproliferative disorders in which the JAK2 signaling pathway isactivated or in which JAK/STAT signaling is dysregulated.

The present invention provides3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amineor a pharmaceutically acceptable salt thereof.

The present invention provides a method of treating chronicmyeloproliferative disorders selected from the group consisting ofpolycythemia vera, essential thrombocytosis, and myelosclerosis withmyeloid metaplasia in a mammal comprising administering to a mammal inneed of such treatment an effective amount of3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amineor a pharmaceutically acceptable salt thereof.

The present invention also provides a method of treating glioblastoma,breast cancer, multiple myeloma, prostate cancer, and leukemias, such asatypical chronic myeloid leukemia, primary and secondary acute myeloidleukemia, T-lineage and B-lineage acute lymphoblastic leukemia,myelodysplasia syndrome, and myeloproliferative disorders in a patientcomprising administering to a patient in need of such treatment aneffective amount of3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amineor a pharmaceutically acceptable salt thereof.

The present invention also provides a pharmaceutical compositioncomprising3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amineor a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable carrier, diluent or excipient.

This invention also provides3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amineor a pharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable carrier, diluent or excipient in combination with anothertherapeutic ingredient.

This invention also provides3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amineor a pharmaceutically acceptable salt thereof for use as a medicament.Additionally, this invention provides use of3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amineor a pharmaceutically acceptable salt thereof in the manufacture of amedicament for treating chronic myeloproliferative disorders. Inparticular these chronic myeloproliferative disorders are selected fromthe group consisting of polycythemia vera, essential thrombocytosis, andmyelosclerosis with myeloid metaplasia. Furthermore, this inventionprovides a pharmaceutical composition for treating chronicmyeloproliferative disorders selected from the group consisting ofpolycythemia vera, essential thrombocytosis, and myelosclerosis withmyeloid metaplasia comprising3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amineor a pharmaceutically acceptable salt thereof as an active ingredient.

It will be understood by the skilled reader that the compound of thepresent invention is capable of forming salts. The compound of thepresent invention is an amine, and accordingly reacts with any of anumber of inorganic and organic acids to form pharmaceuticallyacceptable acid addition salts. Such pharmaceutically acceptable acidaddition salts and common methodology for preparing them are well knownin the art. See, e.g., P. Stahl, et al., HANDBOOK OF PHARMACEUTICALSALTS: PROPERTIES, SELECTION AND USE, (VCHA/Wiley-VCH, 2002); L. D.Bighley, S. M. Berge, D. C. Monkhouse, in “Encyclopedia ofPharmaceutical Technology’. Eds. J. Swarbrick and J. C. Boylan, Vol. 13,Marcel Dekker, Inc., New York, Basel, Hong Kong 1995, pp. 453-499; S. M.Berge, et al., “Pharmaceutical Salts, “Journal of PharmaceuticalSciences, Vol 66, No. 1, January 1977.

The following preparations and examples are named using ChemDraw Ultra,Version 10.0.

Scheme 1 Preparation 1 1-(4-Methoxybenzyl)-5-methyl-1H-pyrazol-3-amineMethod 1

In a 1 L round bottom flask, combine 5-amino-3-methylpyrazole (22.8 g,234.8 mmol) and N-methylpyrrolidone (200 mL). Cool flask to 0° C. andplace under nitrogen. Add sodium hydroxide (9.39 g, 1.0 equivalent(equiv.)) to the flask and stir for 30 minutes (min). Add a solution ofalpha-chloro-4-methoxytoluene (31 mL, 1.0 equiv.) in N-methylpyrrolidone(100 mL) to the flask drop-wise. Let the reaction warm to roomtemperature (RT) slowly overnight. Dilute the reaction with water, andextract with ethyl acetate (EA). Wash the organics with aqueoussaturated sodium chloride. Concentrate in vacuo. Purify on a plug ofsilica (hexane→2:1 hexane:EA→3:2 hexane:EA→1:1 hexane:EA→1:2hexane:EA→EA). Concentrate the desired fractions to give the titlecompound (10.8 g, 21%). LCMS (4 min)=218.0 (M+1).

Method 2 A. (E)-tert-Butyl 2-(4-methoxybenzylidene)hydrazinecarboxylate

Add 4-methoxybenzaldehyde (400 g, 2.94 mol) over 20 min to a solution oftert-butyl carbazate (400 g, 2.94 mol) in toluene (750 mL) at 50° C.Heat to reflux over a period of 1 hour (h), collecting water in anazeotrope with the toluene. After no further water is collected, cool to60° C. Add hexanes until the product precipitates from solution. Coolthe bath further to 20° C. Collect the solids by filtration and dryusing a nitrogen press to afford the title compound (750.5 g, 91%). ¹HNMR [400 MHz, dimethyl sulfoxide-d₆ (DMSO-d₆)] δ 10.6-10.8 (bs, 1H),7.88-8.0 (S, 1H), 7.5-7.55 (d, 2H), 6.95-7.0 (d, 2H), 1.45 (s, 9H).ES/MS (m/z): 249 [M-H].

B. tert-Butyl 2-(4-methoxybenzyl)hydrazinecarboxylate

Add 10% palladium on carbon (water wet, 20 g) slurried in EA (100 mL) toa sealed pressure reactor via vacuum transfer. Rinse transfer line witha minimal amount of EA. Charge (E)-tert-butyl2-(4-methoxybenzylidene)hydrazinecarboxylate (320 g, 1.28 mol) dissolvedin tetrahydrofuran (THF, 1000 mL) via vacuum transfer and rinse linewith a minimal amount of THF. Pressurize the reactor to 50 PSI with H₂and mix the contents of the reactor at 20±10° C. Continue the reaction,maintaining the hydrogen pressure at 50 PSI, until no further hydrogenuptake is observed. Filter the reaction solution to remove the catalystand wash the catalyst filter-cake with THF (500 mL). Add the wash to thereaction filtrate. Concentrate the solution in vacuo to obtain the titlecompound (337 g, 86%) as an oil. ¹H NMR (400 MHz, DMSO-d₆) δ 8.1-8.3 (s,1H), 7.1-7.3 (d, 2H), 6.8-6.9 (d, 2H), 4.4-4.6 (bs, 1H), 3.7-3.8 (s,2H), 3.6-3.7 (s, 3H), 1.3-1.5 (s, 9H).

C. (4-Methoxybenzyl)hydrazine dihydrochloride

To a solution of 4 N hydrogen chloride in dioxane (2000 mL, 8.00 molHCl), add tert-butyl 2-(4-methoxybenzyl)hydrazinecarboxylate (324 g,1.09 mol) dissolved in a minimal amount of dioxane, slowly over a periodof 1 h. A precipitate gradually forms. Allow the solution to stir 16 hat 20±5° C. Collect the solids by filtration. Slurry the solids inheptane (2000 mL) and isolate the solids by filtration. Dry the solidsusing a nitrogen press to give the title compound (242.3 g, 1.08 mol,98%). ¹H NMR (400 MHz, DMSO-d₆) δ 8.2-9.0 (bs, 5H), 7.3-7.4 (d, 2H),6.8-7.0 (d, 2H), 4.0 (s, 2H), 3.7 (s, 3H).

D. 1-(4-Methoxybenzyl)-5-methyl-1H-pyrazol-3-amine and1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-amine

Combine potassium tert-butoxide (191.89 g, 1.71 mol) and THF (2000 mL)at 22° C. Mix until a homogeneous solution is obtained. Cool to 5° C.Add a premixed solution of acetonitrile (84.25 g, 2.05 mol) and methylacetate (126.7 g, 1.71 mol) to the potassium tert-butoxide solution over45 min maintaining a temperature less than 10° C. After the addition iscomplete, allow the reaction to warm to 20±5° C. and stir for about 2 h.Add (4-methoxybenzyl)hydrazine dihydrochloride (250 g) portion-wise tothe reaction over about 5 min, followed by 4 N hydrogen chloride indioxane (262.5 g, 1.00 mol) at a rate that maintains the temperature<30° C. When the addition is complete, allow to stir at 25±5° C. forabout 16 h. Isolate the solids by filtration and wash with THF (500 mL).Slurry the crude solids in dichloromethane (DCM, 4 L) and water (2 L)adjusting the pH to >10 with 5 N NaOH. Allow the layers to settle andcollect the organic phase. Wash the aqueous phase with DCM (2 L).Combine the organic phases and dry over anhydrous sodium sulfate andconcentrate the solution to a solid in vacuo to afford 165 g of thecrude. Heat the crude in isopropyl acetate (660 mL) to reflux todissolve as many solids as possible. Cool to 33° C. and add hexane (600mL) slowly over 1 h. Cool to 10° C. and maintain the temperature at 10°C. for 10 min. Isolate the solids by filtration, wash with hexane (200mL), and dry using a nitrogen press to afford a mixture of the titlecompounds (91.5 g, 0.4 mol, 47%). ¹H NMR (400 MHz, DMSO-d₆) δ 7.2-7.3(d, 2H), 6.7-6.9 (d, 2H), 5.1 (bs, 2H), 5.0 (s, 1H), 4.9 (s, 2H),3.6-3.8 (s, 3H), 1.9 (s, 3H).

Note: these intermediates can be separated by chromatography; however inthis case, they are isolated as a mixture and can be used in the finalsequence below which involves removal of the benzyl protection groupresulting in the same product.

Preparation 2 2-Chloro-1-(4-chloro-2-fluorophenyl)ethanone

In a 1 L round bottom flask combine 4′-chloro-2′-fluoroacetophenone (40g, 231.8 mmol), heptane (120 mL), and methanol (16 mL). Cool to 0° C.and place under nitrogen. Dissolve sulfuryl chloride (21.5 mL, 1.15equiv.) in heptane (120 mL) and charge to an addition funnel. Adddrop-wise to the reaction over 60 min. Stir for 2.5 h at 0° C.; a whiteprecipitate forms during this time. Charge the addition funnel with 1 Msodium bicarbonate (400 mL) then add to the reaction drop-wise. Afterall gas evolution stops, filter the biphasic suspension to collect thetitle compound (38.18 g, 80%) as white needles. ¹H NMR (DMSO-d₆) δ 5.00(d, 2H, J=2.5 Hz), 7.43 (m, 1H), 7.63 (m, 1H), 7.89 (t, 1H, J=8.4 Hz).

Preparation 3 (E)-N′-(6-Chloropyridazin-3-yl)-N,N-dimethylacetimidamide

In a 2 L round bottom flask combine 3-chloro-6-pyridazinamine (43.2 g,333.5 mmol), toluene (500 mL), and N,N-dimethylacetamide dimethyl acetal(67.8 mL, 1.25 equiv.). Attach a reflux condenser then heat to refluxfor 2 h. Let cool to RT. Concentrate in vacuo. Triturate the crudematerial with hexanes and filter to isolate the title compound (60.4 g,91%) as a light tan solid. MS=199.0 (M+1).

Preparation 4(4-Chloro-2-fluorophenyl)(6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl)methanone

In a round bottom flask combine(E)-N′-(6-chloropyridazin-3-yl)-N,N-dimethylacetimidamide (36.61 g,184.3 mmol), 2-chloro-1-(4-chloro-2-fluorophenyl)ethanone (38.15 g, 1equiv.), and dimethylformamide (150 mL). Place under nitrogen then heatat 120° C. for 4 h. Let cool to RT and stir overnight. Dilute with EA (1L) and water (500 mL). Extract organics three times with water followedby aqueous saturated sodium chloride aqueous. Dry organics overanhydrous magnesium sulfate. Filter and concentrate in vacuo. Purify bysilica plug (hexane→4:1 hexane:EA →3:1 hexane:EA→2:1 hexane:EA→1:1hexane:EA) and isolate the title compound (33.8 g, 57%) as a light greensolid. LCMS (4 min=324.0, 326.0, M+1).

Preparation 52-((6-Chloro-3-(4-chloro-2-fluorobenzoyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)methyl)isoindoline-1,3-dione

Combine(4-chloro-2-fluorophenyl)(6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl)methanone(5.6 g, 17.3 mmol), N-phthaloylglycine (6.0 g, 1.7 equiv.), acetonitrile(60 mL), water (15 mL), trifluoroacetic acid (0.26 mL, 0.2 equiv.), andsilver nitrate (294 mg, 0.1 equiv.) in a round bottom flask withattached addition funnel and place under nitrogen. Heat to 70° C. andmaintain at this temperature for 15 min. Dissolve ammonium persulfate(7.1 g, 1.8 equiv.) in water (15 mL) and charge to an addition funnel.Add drop-wise to the reaction flask over approximately 20 min. Heatreaction at 70° C. for 1 h. A precipitate forms during this time; filtervia Buchner funnel to isolate the title compound crude (7.3 g, 87%) asan off-white solid. LCMS (4 min)=483.0, 485.0, M+1).

Preparation 6(8-(Aminomethyl)-6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl)(4-chloro-2-fluorophenyl)methanone

Combine2-((6-chloro-3-(4-chloro-2-fluorobenzoyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)methyl)isoindoline-1,3-dione(7.30 g, 15.1 mmol), ethanol (200 mL), and hydrazine (1.45 mL, 3 equiv.)in a round bottom flask and place under nitrogen. Stir for 2 days at RT.Heat for 2 h at 50° C. then concentrate the reaction in vacuo. Dilutewith EA. Wash the organics with 1N HCl (aq) to pull product into theaqueous layer. Make the aqueous layer basic with 1N NaOH (aq) andextract with EA. Wash the EA layer with aqueous saturated sodiumchloride, and dry over anhydrous magnesium sulfate. Filter andconcentrate in vacuo to give the title compound crude (1.2 g, 23%) as alight green solid. MS=355.0, 353.0 (M+1).

Preparation 7(4-Chloro-2-fluorophenyl)(6-chloro-2-methyl-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-3-yl)methanone

Combine(8-(aminomethyl)-6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl)(4-chloro-2-fluorophenyl)methanone(1.15 g, 3.3 mmol), water (12 mL), potassium carbonate (495 mg, 1.1equiv.), and 2-bromoethyl ether (0.47 mL, 1.1 equiv) in a 20 mLmicrowave reaction vessel. Seal with a crimp cap then heat in amicrowave reactor at 120° C. for 20 min. Cool to RT and partitionbetween EA and water. Wash EA layer with aqueous saturated sodiumchloride, and dry over anhydrous magnesium sulfate. Filter andconcentrate in vacuo. Purify on silica gel (4:1 hexane:EA→2:1hexane:EA→1:1 hexane:EA) to give the title compound (0.43 g, 31%) as alight yellow foam. LCMS (4 min)=423.0, 425.0, M+1.

Preparation 8(4-Chloro-2-fluorophenyl)(6-chloro-2-methyl-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-3-yl)methanol

Combine(4-chloro-2-fluorophenyl)(6-chloro-2-methyl-8-(morpholinomethyl)-imidazo[1,2-b]pyridazin-3-yl)methanone(0.43 g, 1.0 mmol) and methanol (15 mL) in a round bottom flask. Placeunder nitrogen and cool to 0° C. Add sodium borohydride (58 mg, 1.5equiv.) in one portion. Stir for 5 min at this temperature then removecooling bath and let warm to RT. After 15 min, quench the reaction withwater then extract with EA. Wash the organics with water followed byaqueous saturated sodium chloride. Dry the organics over anhydrousmagnesium sulfate. Filter and concentrate in vacuo to give the titlecompound (0.4 g, 93%). LCMS (4 min)=425.0, 427.0, M+1.

Preparation 94-((6-Chloro-3-(4-chloro-2-fluorobenzyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)methyl)morpholine

Combine(4-chloro-2-fluorophenyl)(6-chloro-2-methyl-8-(morpholinomethyl)-imidazo[1,2-b]pyridazin-3-yl)methanol(0.4 g, 0.94 mmol), 1,2-dichloroethane (25 mL), triethylsilane (0.45 mL,3 equiv.), and trifluoroacetic acid (0.57 mL, 8 equiv.) in a roundbottom flask and place under nitrogen. Heat at 70° C. overnight.Concentrate reaction in vacuo. Load onto a Varian MegaElut® 10 gram SCXion exchange cartridge (prewashed with methanol). Elute with methanol toremove non-basic impurities. Elute with 2 M ammonia in methanol.Concentrate in vacuo to give the title compound (0.36 g, 94%). LCMS (4min)=409.0, 411.0, M+1.

Preparation 103-(4-Chloro-2-fluorobenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-2-methyl-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine

Combine4-((6-chloro-3-(4-chloro-2-fluorobenzyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)methyl)morpholin(0.36 g, 0.88 mmol), 1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-amine(0.248 g, 1.3 equiv.), potassium carbonate (0.30 g, 2.5 equiv.),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.076 g, 0.15 equiv.),water (2 mL), and 1,4-dioxane (20 mL) in a round bottom flask. Degasthoroughly with nitrogen then add bis(dibenzylideneacetone)palladium(0.10 g, 0.2 equiv.). Attach a reflux condenser and place undernitrogen. Heat the reaction at reflux overnight. Pass reaction through aCelite plug. Wash the plug with EA. Transfer to a separatory funnel andwash with water. Wash the organic layer with aqueous sodium chloride,and dry over anhydrous magnesium sulfate. Filter and concentrate invacuo. Purify on silica gel (EA→10% methanol:EA) to give the titlecompound (0.447 g, 86%) as a pale yellow solid. LCMS (4 min)=590.2,591.2, M+1.

EXAMPLE 1

3-(4-Chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine

Combine3-(4-chloro-2-fluorobenzyl)-N-(1-(4-methoxybenzyl)-5-methyl-1H-pyrazol-3-yl)-2-methyl-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine(0.447 g, 0.76 mmol) and trifluoroacetic acid (10 mL) in a 20 mLmicrowave reactor tube. Seal with a crimp cap then heat in a microwavereactor at 120° C. for 20 min. Partition between EA and water that ismade basic with excess NaOH aqueous. Wash the organic phase three timeswith NaOH aqueous followed by aqueous saturated sodium chloride. Dryover anhydrous magnesium sulfate. Filter and concentrate in vacuo.Purify on silica gel (EA→10% methanol:EA) to give the title compound(0.246 g, 0.52 mmol) as a pale yellow solid. LCMS (8 min)=470.0, M+1.

EXAMPLE 2

3-(4-Chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-aminehydrochloride

Combine3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine(0.1 g, 0.21 mmol) and 1,4-dioxane (10 mL) in a pear flask and placeunder nitrogen. Add hydrogen chloride (4 M in 1,4-dioxane, 0.053 mL, 1.0equiv.) and let stir at RT under nitrogen for 1.5 h. Concentrate invacuo then evaporate under vacuum from absolute ethanol two times. Dryovernight in a vacuum oven (60° C.) to give the title compound (0.11 g,102%). LCMS (8 min)=470.0, M+1.

Scheme 2 Preparation 11(E)-N′-(6-chloropyridazin-3-yl)-N,N-dimethylacetimidamide

Combine 6-chloropyridazin-3-amine (1.500 kg, 11.58 mol);1,1-dimethoxy-N,N-dimethylethanamine (2.313 kg, 17.37 mol) andcyclopentyl methyl ether (8.25 L) then heat to 98° C. while distillingoff the resulting methanol byproduct. After 4 h, the reaction mixture iscooled to ambient temperature and heptanes (11.2 L) is added to thereaction solution for crystallizing the product. The title compound iscollected by filtration and is dried. (1.494 kg, 64.95%; mp=73° C.)

Preparation 12 2-chloro-1-(4-chloro-2-fluorophenyl)ethanone

Stir a mixture of heptanes (1.5 L), methanol (0.4 L), and1-(4-chloro-2-fluorophenyl)ethanone (1 kg, 5.81 mol) with cooling to <5°C. Add sulfuryl chloride (0.608 L, 1.02 kg, 7.55 mol) as a heptanes (1.5L) solution drop-wise to the mixture keeping the reaction temperature<15° C. during the addition. After 2 h quench the reaction at ambienttemperature to a pH of 6 with sodium hydroxide (5N, 2.0 L). Extract thereaction mixture with methylene chloride (2 L) and concentrate theextract to form a white solid. Filter and dry the solid.

Preparation 13(4-chloro-2-fluorophenyl)(6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl)methanone

Combine 2-chloro-1-(4-chloro-2-fluorophenyl)ethanone (1.5 kg, 5.44 mol),and (E)-N′-(6-chloropyridazin-3-yl)-N,N-dimethylacetimidamide (1.19 kg,5.72 mol) in DMF (10.14 L) and heat at 120° C. for 5 h. After cooling,add water (30 L) and stir to crystallize the product. Collect theproduct by filtration and rinse the cake with water (2×12 L) andheptanes (2×10 L) then dry under vacuum to obtain title compound. (1.490kg, 84.44%; mp=160° C., M+=324).

Preparation 14(4-chloro-2-fluorophenyl)(6-chloro-2-methyl-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-3-yl)methanone

Add ethanol (12 L),(4-chloro-2-fluorophenyl)(6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl)methanone(897.70 g, 2.77 mol) and bis(2,4-pentanedionato)-oxovanadium (IV)(146.81 g, 553.67 mmol) to a reaction vessel with a nitrogen atmosphere.Add an ethanol (6 L) solution of 4-methylmorpholine 4-oxide (3.89 kg,33.21 mol) drop-wise over 150 min keeping the reaction temperature at23-33° C.; then heat the reaction at 40° C. for 48 h. Cool the reactionand concentrate by removal of solvent (13 L). Filter the resultingmixture, rinse the filter cake with hexane (1 L) and then dry. (728 g,66.25%; mp 145-147° C.; M+=423).

Preparation 154-((6-chloro-3-(4-chloro-2-fluorobenzyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)methyl)morpholinehydrochloride

At 26° C., combine triethylsilane (110 g, 946 mmol) and(4-chloro-2-fluorophenyl)(6-chloro-2-methyl-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-3-yl)methanone(50.1 g, 117.06 mmol) to form a solution. Add trifluoro acetic acid (150mL, 1.98 mol) to the reaction mixture then heat at 78° C. for 24 h. Coolthe reaction to ambient temperature and separate the mixture to removethe top layer. Dissolve the bottom layer with ethyl acetate (1 L) andadjust the pH to 11 with sodium hydroxide (4 N, 500 mL). Separate theorganic layer and add HCl (4 M in ethyl ether) to the organic layer toform the HCl salt. Filter and dry the HCl salt. (100 g (96%);mp=237-238° C.; M+=409).

Preparation 163-(4-Chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-aminehydrochloride and freebase

Prepare active catalyst by combining palladium chloride (160 mg, 0.90mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.10 g, 1.84mmol) in DMF (25 mL) and warming to form a solution. Add the preformedcatalyst to a solution of 3-methyl-1H-pyrazol-5-amine (3.0 g, 29.65mmol),4-((6-chloro-3-(4-chloro-2-fluorobenzyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)methyl)morpholinehydrochloride (9.0 g, 20.19 mmol), potassium bicarbonate (6.0 g, 59.93mmol) in DMF (65 mL) and heat to 150° C. for 1 h. Cool the reaction to60° C. and add mercaptopropyl functionalized silica (500 mg) and stirfor 1 h then filter to remove the silica. Cool to ambient temperature,add 2-methyltetrahydrofuran (125 mL) and extract with water to removeDMF. Add HCl to the organic solution to form the3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-aminehydrochloride salt. Add the HCl salt (1.1 g) to sodium hydroxide (10 mL,1N) in n-butanol (10 mL) and stir. Filter the resulting mixture toobtain 0.22 g of the free base, imidazo[1,2-b]pyridazin-6-amine,3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl),(22% yield, M+1.=470).

EXAMPLE 3 Formulation of3-(4-Chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine

Optionally pass3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amineand excipients through an appropriate screen. Combine and blend3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine,Pregelatinized Starch, and Pregelatinized Starch with 5% Dimethiconeusing an appropriate tumble bin (with or without intensifier bar) orother suitable mixing equipment. Alternately, add dimethicone duringblending via a liquid addition system. Fill the blended powder intocapsules using suitable encapsulation equipment. Monitor weightuniformity and appropriate in-process parameters during the fillingprocess. Optionally dedust the final capsules or polish by either manualor automated processes.

JAK2 EPO-TF1/pSTAT5 Cell-Based Assay Cellomics ArrayScan® HCS

JAK2 EPO-TF1/pSTAT5 cell-based assay mimics the constitutive activationof JAK2-STAT5 in erythroid progenitor cells, which drives theoverproduction of red blood cells, a marker of polycythemia vera (PV).

TF-1 (human erythroid leukemia) cells are maintained in RPMI 1640(RPMI-1640 was developed by Moore et. al. at Roswell Park MemorialInstitute. The formulation is based on the RPMI-1630 series of mediautilizing a bicarbonate buffering system and alterations in the amountsof amino acids and vitamins.) with 10% fetal bovine serum (FBS), 0.075%sodium bicarbonate, 1 mM sodium pyruvate, 1× antibiotic/antimycotic(Invitrogen, Carlsbad, Calif.) and 0.45% glucose. The medium issupplemented with GM-CSF (granulocyte-macrophage colony-stimulatingfactor) at a final concentration of 2 ng/mL. Cells are kept at 37° C.with 5% CO₂. Cells are starved in serum free medium to remove endogenousgrowth factors. TF-1 cells are counted and cells are collected to seed2×10⁷ cells per 96-well plate at a density of 2×10⁵ cells per well. Thecells are rinsed twice with unsupplemented RPMI 1640 (RPMI 1640 with0.075% sodium bicarbonate, 1 mM sodium pyruvate, 1×antibiotic/antimycotic, and 0.45% glucose) before suspending cells at afinal concentration of 5×10⁵ cells/mL in RPMI with 0.6% FBS. The dilutedcells are added back to tissue culture flasks and incubated overnight at37° C. Test compounds are prepared in 100% DMSO at 10 mM concentration.Compounds are serially diluted 1:3 with 100% DMSO in a 10 point-200×concentration-response range (4 mM-200 nM). In a separate 96 deep wellplate 2.5 μL of 200× compound solution is added to 125 μL of completeRPMI 1640 media with 10% FBS for a 4× concentration compound plate.

To perform the assay, serum-starved cells are collected and washed oncewith unsupplemented RPMI 1640 medium. Cells are suspended in 10% FBScomplete RPMI medium for a final concentration of 8×10⁵ cells/mL. Analiquot of 250 μL of diluted cells (2×10⁵ cells) are added to each wellin the 4× concentration compound plate. Cells are mixed by vortexing andthe plate is incubated in a 37° C. water bath for 10 min. A fresh 4×working solution of Erythropoietin (EPO) at 6.4 Units/mL is prepared byusing pre-warmed 10% FBS complete RPMI 1640 medium. After the cells aretreated with compound for 10 min, 125 μL of EPO medium is added intoeach well and the plate is vortexed. Cells are incubated in a 37° C.water bath for 20 min and mixed every 5 min during the incubation time.Final 10 point concentration-response range is 20 μM-1 nM at a finalconcentration of DMSO at 0.5% and EPO at 1.6 U/mL. After cell treatment,500 μL of 1% formaldehyde solution (made freshly with phosphate-bufferedsaline (PBS) and kept warm at 37° C.) is added to each well. Plates aresealed and inverted 8-10 times to mix. Plates are placed in a 37° C.water bath for 10 min. After incubation, cell plates are spun at 1200rpm for 5 min at room temperature (RT). The supernatant is aspirated,leaving 100 μL of cells (2×10⁵ cells). The cells are vortexed and washedtwice with 800 μL of PBS by repeating the spin steps and leaving 100 μLcontaining ˜2×10⁵ cells after the final wash. An aliquot of 800 μL ofcold 90% methanol is added to the cells and placed at −20° C. overnight.Plates are spun and methanol is removed. Cells are washed with FACSbuffer (PBS with 5% FBS and 0.02% sodium azide). An aliquot of 200 μL of1 to 10 dilution of Mouse anti-pSTAT5 (pY694) Alexa Fluor 647® influorescence activated cell sorting (FACS) buffer is added to the cells.Cells are mixed well and incubated at RT in the dark for 2 h. Cells arewashed once with PBS and 100 μL of cells are left. A working solution of2 mg/mL Hoechst (Acros Organics, Morris Plains, N.J.) is prepared withPBS. An aliquot of 200 μL is added to each well and cells are incubatedat RT in the dark for 10 min. Cells are washed with PBS, and 50 μL ofCytofix (BD Biosciences, San Jose, Calif.) is added to the cells. Thecells are transferred to 96 well black tissue culture plates and sealed.The plates are spun down. Mean fluorescent intensity data are collectedand analyzed using Cellomics Arrayscan® VTi. Compound treatment iscompared to the vehicle to determine percent inhibition data. Theminimum significant ratio (MSR) between two test compounds withdifferent IC₅₀s is determined to be 2.2. The relative IC₅₀ is calculatedusing a 4 parameter logistic curve fitting analysis with ActivityBase4.0. For3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine,the IC₅₀=0.033 μM, n=4. The results of this assay demonstrate that3-(4-chloro-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amineis a potent JAK2 inhibitor.

JAK3 IL-2-NK-92/pSTAT5 Cell-Based Assay Cellomics ArrayScan® HCS

IL-2 activates the JAK3 pathway in natural killer (NK) cells to drivethe NK and CD8 lymphocyte proliferation. Therefore, IL-2 stimulatedNK92/pSTAT5 cell-based assay enables the evaluation of the JAK3 cellularactivity of JAK2 compounds in vitro.

NK-92 (natural killer) cells (ATCC, Manassas, Va.) are maintained inminimum essential medium (MEM) Alpha with 15% fetal bovine serum, 15%Horse Serum and 1× antibiotic/antimycotic (Invitrogen, Carlsbad,Calif.). The medium is supplemented with IL-2 (R&D systems, Minneapolis,Minn.) for a final concentration of 4 ng/mL. Cells are kept at 37° C.with 5% CO₂. Cells are starved in serum free medium to remove endogenousgrowth factors. NK-92 cells are counted and collected to seed 2×10⁷cells per 96-well plate at a density of 2×10⁵ cells per well. The cellsare rinsed twice with unsupplemented MEM Alpha (MEM Alpha) beforesuspending cells at a final concentration of 8×10⁵ cells/mL in MEM Alphawith 0.6% serum (0.3% FBS, 0.3% horse serum). The diluted cells areadded back to tissue culture flasks and incubated overnight at 37° C.Test compounds are prepared in 100% DMSO at 10 mM concentration.Compounds are serially diluted 1:3 with 100% DMSO in a 10 point-200×concentration-response range (4 mM-200 nM). In a separate 96 deep wellplate 2.5 μL of 200× compound solution is added to 125 μL of 10% FBScomplete RPMI 1640 medium for a 4× concentration compound plate.

To perform the assay, serum-starved cells are collected and washed oncewith unsupplemented RPMI 1640 medium. Cells are suspended in 10% FBScomplete RPMI 1640 medium for a final concentration of 8×10⁵ cells/mL.An aliquot of 250 μL of diluted cells (2×10⁵ cells) is added to eachwell in the 4× concentration compound plate. Cells are mixed byvortexing and the plate is incubated in a 37° C. water bath for 10 min.A fresh 4× working solution of IL-2 at 2 ng/mL is prepared usingpre-warmed 10% FBS complete RPMI medium. After the cells are treatedwith compound for 10 min, 125 μL of IL-2 medium is added into each well.Cells are mixed by vortexing. Cells are incubated in a 37° C. water bathfor 20 min and mixed every 5 min during the incubation time. Final 10point concentration-response range is 20 μM-1 nM at a finalconcentration of DMSO at 0.5% and IL-2 at 0.5 ng/mL. After celltreatment, 500 μL of 1% formaldehyde solution (made freshly withphosphate-buffered saline (PBS) and kept warm at 37° C.) is added toeach well. Plates are sealed and inverted 8-10 times to mix. Plates areplaced in a 37° C. water bath for 10 min. After incubation, cell platesare spun at 1200 rpm for 5 min at RT. The supernatant is aspirated,leaving 100 μL of cells (2×10⁵ cells). The cells are vortexed and washedtwice with 800 μL of PBS by repeating the spin steps and leaving 100 μLcontaining ˜2×10⁵ cells after the final wash. An aliquot of 800 μL ofcold 90% methanol is added to the cells and placed at −20° C. overnight.Plates are spun and methanol is removed. Cells are washed with FACSbuffer (PBS with 5% FBS and 0.02% sodium azide). An aliquot of 200 μL of1 to 10 dilution of Mouse anti-pSTAT5 (pY694) Alexa Fluor 647® influorescence activated cell sorting (FACS) buffer is added to the cells.Cells are mixed well and incubated at RT in the dark for 2 h. Cells arewashed once with PBS and 100 uL of cells are left. A working solution of2 mg/mL Hoechst (Acros Organics, Morris Plains, N.J.) is prepared withPBS. An aliquot of 200 μL is added to each well and cells are incubatedat RT in the dark for 10 min. Cells are washed with PBS, and 50 μL ofCytofix® (BD Biosciences, San Jose, Calif.) is added to the cells. Thecells are transferred to 96 well black tissue culture plates and sealed.The plates are spun down. Mean fluorescent intensity data are collectedand analyzed using Cellomics Arrayscan® VTi. Compound treatment iscompared to the vehicle to determine percent inhibition data. The MSR isdetermined to be 2.06. The relative IC₅₀ is calculated using a 4parameter logistic curve fitting analysis with ActivityBase 4.0. For3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine,the IC₅₀=0.94 μM, n=4. The results of the JAK3 IL2-NK92-pSTAT5cell-based assay demonstrate that3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo-[1,2-b]pyridazin-6-amineis a less potent inhibitor of JAK3 (when compared to the results of theJAK2 EPO-TF1/pSTAT5 cell based assay with an IC₅₀=0.033 uM). From theseresults, the ratio of JAK3/JAK2, the IC₅₀ was determined to be 28.5fold, which demonstrates3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amineis a selective JAK2 inhibitor over JAK3.

Ba/F3JAK2V617F Cell-Based Assay Cellomics ArrayScan® HCS

JAK2 target inhibition has been evaluated in Ba/F3 expressing JAK2 V617Fby Western blot as reported in Wernig et al. (Wernig G, et al. Efficacyof TG101348, a selective JAK2 inhibitor, in treatment of a murine modelof JAK2V617F-induced polycythemia vera, Cancer Cell, April;13(4):311-20). A medium throughput Cellomics assay was established toevaluate the JAK2 target inhibition in Ba/F3 cells expressing JAK2V617F.This assay enables the discovery of an effective therapeutic agent totreat disorders associated with JAK2V617F mutation.

Ba/F3 (murine pro-B) cells expressing JAK2V617F maintained in RPMI 1640with 10% FBS, 0.07% sodium bicarbonate, 1 mM sodium pyruvate, 1×antibiotic/antimycotic (Invitrogen, Carlsbad, Calif.) and 0.45% glucose(Sigma, St Louis, Mo.). Cells are kept at 37° C. with 5% CO₂. The testcompound is prepared in 100% DMSO at 10 mM concentration. The compoundis serially diluted 1:3 with 100% DMSO in a 10 point 200×concentration-response range (4 mM-200 nM.). In a separate 96 deep wellplate 2.5 μL of 200× compound solution is added to 125 μL of completeRPMI 1640 media with 10% FBS for a 4× concentration compound plate.

To perform the assay, cells are collected and washed twice withunsupplemented RPMI 1640. Cells are then suspended in 10% FBS completedRPMI medium for a final concentration of 4×10⁵/mL. Next, 500 mL of cells(2×10⁵ cells) are transferred into 96 deep well plates. Finally, 2.5 μL(1:200 dilution) of compound stock solution are added to the cells andare incubated with cells in a 37° C. water bath for 60 min.

After cell treatment, 500 μL of 1% formaldehyde solution (made freshlywith phosphate-buffered saline (PBS) and kept warm at 37° C.) is addedto each well. Plates are sealed and inverted 8-10 times to mix. Platesare placed in a 37° C. water bath for 10 min. After incubation, cellplates are spun at 1200 rpm for 5 min at RT. The supernatant isaspirated, leaving 100 μL of cells (2×10⁵ cells). The cells are vortexedand washed twice with 800 μL of PBS by repeating the spin steps andleaving 100 μL containing ˜2×10⁵ cells after the final wash. An aliquotof 800 μL of cold 90% methanol is added to the cells and placed at −20°C. overnight. Plates are spun and methanol is removed. Cells are washedwith FACS buffer (PBS with 5% FBS and 0.0% sodium azide). An aliquot of200 μL of 1 to 10 dilution of Mouse anti-pSTAT5 (pY694) Alexa Fluor 647®in fluorescence activated cell sorting (FACS) buffer is added to thecells. Cells are mixed well and incubated at RT in the dark for 2 h.Cells are washed once with PBS and 100 μL of cells are left. A workingsolution of 2 mg/mL Hoechst (Acros Organics, Morris Plains, N.J.) isprepared with PBS. An aliquot of 200 μL is added to each well and cellsare incubated at RT in the dark for 10 min. Cells are washed with PBS,and 50 μL of Cytofix® (BD Biosciences, San Jose, Calif.) is added to thecells. The cells are transferred to 96 well black tissue culture platesand sealed. The plates are spun down. Mean fluorescent intensity dataare collected and analyzed using Cellomics Arrayscan® VTi. Compoundtreatment is compared to the vehicle to determine percent inhibitiondata. The relative IC₅₀ is calculated using a 4 parameter logistic curvefitting analysis with ActivityBase 4.0. For3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine,the IC₅₀=0.03 μM. The results of this assay demonstrate that3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amineeffectively inhibits the JAK2V617F target in Ba/F3 cells expressingJAK2V617F gene.

The compounds of the present invention are preferably formulated aspharmaceutical compositions administered by a variety of routes. Mostpreferably, such compositions are for oral administration. Suchpharmaceutical compositions and processes for preparing same are wellknown in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OFPHARMACY (A. Gennaro, et al., eds., 19^(th) ed., Mack Publishing Co.,1995).

The compounds of the present invention are generally effective over awide dosage range. For example, dosages per day normally fall within therange of about 1 mg to about 1000 mg total daily dose, preferably 500 mgto 1000 mg total daily dose, more preferably 600 mg to 1000 mg totaldaily dose. In some instances dosage levels below the lower limit of theaforesaid range may be more than adequate, while in other cases stilllarger doses may be employed. The above dosage range is not intended tolimit the scope of the invention in any way. It will be understood thatthe amount of the compound actually administered will be determined by aphysician, in the light of the relevant circumstances, including thecondition to be treated, the chosen route of administration, the actualcompound or compounds administered, the age, weight, and response of theindividual patient, and the severity of the patient's symptoms.

1.3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine,or a pharmaceutically acceptable salt thereof.
 2. A compound accordingto claim 1 which is3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine.3. A compound according to claim 1 which is3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-aminehydrochloride.
 4. A method of treating chronic myeloproliferativedisorders selected from the group consisting of polycythemia vera,essential thrombocytosis, and myelosclerosis with myeloid metaplasia ina mammal comprising administering to a mammal in need of such treatmentan effective amount of3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine,or a pharmaceutically acceptable salt thereof.
 5. A method of treatingglioblastoma, breast cancer, multiple myeloma, prostate cancer, andleukemias, such as atypical chronic myeloid leukemia, primary andsecondary acute myeloid leukemia, T-lineage and B-lineage acutelymphoblastic leukemia, myelodysplasia syndrome, and myeloproliferativedisorders in a patient comprising administering to a patient in need ofsuch treatment an effective amount of3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine,or a pharmaceutically acceptable salt thereof.
 6. A pharmaceuticalcomposition comprising a compound according to claim 3 and apharmaceutically acceptable carrier, diluent or excipient.
 7. A compoundaccording to claim 3 for use as a medicament.
 8. A compound according toclaim 3 for use in the treatment of glioblastoma, breast cancer,multiple myeloma, prostate cancer, and leukemias, T-lineage andB-lineage acute lymphoblastic leukemia, myelodysplasia syndrome, andmyeloproliferative disorders.
 9. A compound for use according to claim8, or a pharmaceutically acceptable salt thereof, in the treatment ofchronic myeloproliferative disorders.
 10. A method of treatingconditions associated with activity of mutant JAK2 in a patient in needthereof, which comprises administering to said patient a compoundaccording to claim
 3. 11. A pharmaceutical composition comprising acompound according to claim 1, or a pharmaceutically acceptable saltthereof, and a pharmaceutically acceptable carrier, diluent orexcipient.
 12. A compound according to claim 1, or a pharmaceuticallyacceptable salt thereof, for use as a medicament.
 13. A compoundaccording to claim 1, or a pharmaceutically acceptable salt thereof, foruse in the treatment of glioblastoma, breast cancer, multiple myeloma,prostate cancer, and leukemias, T-lineage and B-lineage acutelymphoblastic leukemia, myelodysplasia syndrome, and myeloproliferativedisorders.
 14. A compound for use according to claim 13, or apharmaceutically acceptable salt thereof, in the treatment of chronicmyeloproliferative disorders.
 15. A method of treating conditionsassociated with activity of mutant JAK2 in a patient in need thereof,which comprises administering to said patient a compound according toclaim 1, or a pharmaceutically acceptable salt thereof.